# The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial

> **NCT03509688** · NA · COMPLETED · sponsor: **The First Hospital of Jilin University** · enrollment: 312 (actual)

## Conditions studied

- Hepatitis

## Interventions

- **DRUG:** entecavir+resveratrol
- **DRUG:** Entecavir
- **DRUG:** entecavir+thymosin α1

## Key facts

- **NCT ID:** NCT03509688
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2018-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509688, "The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03509688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*